Truist raised the firm’s price target on Encompass Health (EHC) to $116 from $108 and keeps a Buy rating on the shares. The company reported strong Q3 results ahead of consensus estimates driven by ongoing volume momentum and solid cost management, and the firm continues to see a sizable market opportunity for Encompass, with labor trends “stable or improving”, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Reports Strong Q3 2024 Results
- Encompass Health price target raised to $117 from $115 at KeyBanc
- Encompass Health price target raised to $116 from $109 at Barclays
- Encompass Health raises FY24 adj. EPS $4.19 -$4.33 from $3.97-$4.22
- Encompass Health reports Q3 cont. ops. EPS $1.07, consensus 94c